DK3199951T3 - Arginin-vasopressin-prohormon som prædiktiv biomarkør for diabetes - Google Patents

Arginin-vasopressin-prohormon som prædiktiv biomarkør for diabetes Download PDF

Info

Publication number
DK3199951T3
DK3199951T3 DK16205552.9T DK16205552T DK3199951T3 DK 3199951 T3 DK3199951 T3 DK 3199951T3 DK 16205552 T DK16205552 T DK 16205552T DK 3199951 T3 DK3199951 T3 DK 3199951T3
Authority
DK
Denmark
Prior art keywords
prohormon
biomarket
vasopressin
predictive
arginine
Prior art date
Application number
DK16205552.9T
Other languages
Danish (da)
English (en)
Inventor
Joachim Struck
Andreas Bergmann
Olle Melander
Christopher Newton-Cheh
Thomas J Wang
Original Assignee
Brahms Gmbh
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brahms Gmbh, Massachusetts Gen Hospital filed Critical Brahms Gmbh
Application granted granted Critical
Publication of DK3199951T3 publication Critical patent/DK3199951T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G01N2410/04Oxytocins; Vasopressins; Related peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK16205552.9T 2008-10-31 2009-10-29 Arginin-vasopressin-prohormon som prædiktiv biomarkør for diabetes DK3199951T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08168096 2008-10-31
EP09744978.9A EP2356463B1 (en) 2008-10-31 2009-10-29 Arginine vasopressin pro-hormone as predictive biomarker for diabetes

Publications (1)

Publication Number Publication Date
DK3199951T3 true DK3199951T3 (da) 2020-02-24

Family

ID=40445457

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16205552.9T DK3199951T3 (da) 2008-10-31 2009-10-29 Arginin-vasopressin-prohormon som prædiktiv biomarkør for diabetes

Country Status (7)

Country Link
US (2) US9116153B2 (enExample)
EP (2) EP3199951B1 (enExample)
JP (2) JP5785086B2 (enExample)
CN (3) CN102317788A (enExample)
DK (1) DK3199951T3 (enExample)
ES (2) ES2645688T3 (enExample)
WO (1) WO2010049179A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2016394A4 (en) 2006-04-04 2013-04-24 Singulex Inc METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
AU2010259022B2 (en) 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
US20130149386A1 (en) * 2011-12-07 2013-06-13 Region Nordjylland Cd36 as biomarker for steatosis
US20130338027A1 (en) * 2012-06-15 2013-12-19 Nuclea Biotechnologies, Inc. Predictive Markers For Cancer and Metabolic Syndrome
JP6196034B2 (ja) 2012-12-20 2017-09-13 ライオン株式会社 高血糖リスク判定用マーカーペプチドおよびその用途
CN103266089A (zh) * 2013-05-09 2013-08-28 南京医科大学第一附属医院 抗人和肽素单克隆抗体mcco1及其应用
US20160097781A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Method for stratifying a female subject for hormone replacement therapy
CA3134929A1 (en) * 2019-03-28 2020-10-01 Lundoch Diagnostics AB Use of follistatin in type 2 diabetes risk prediction
CN113238063A (zh) * 2021-05-31 2021-08-10 迈克生物股份有限公司 Gdf15评估代谢综合征患者进展为心血管疾病的应用
CN113248590B (zh) * 2021-06-24 2021-09-10 天津奇云诺德生物医学有限公司 一种NT-proBNP蛋白抗原决定簇多肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606016D0 (en) * 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
DE60335387D1 (de) * 2002-07-16 2011-01-27 Woomera Therapeutics Inc Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen
EP1673465A4 (en) * 2003-09-29 2008-04-30 Biosite Inc PROCESS AND COMPOSITIONS FOR SEPSIS DIAGNOSIS
EP1628136A1 (en) * 2004-08-19 2006-02-22 B.R.A.H.M.S. Aktiengesellschaft Method of diagnosis of disease using copeptin
US20070218519A1 (en) * 2005-10-11 2007-09-20 Tethys Bioscience, Inc. Diabetes-associated markers and methods of use thereof
JP5855332B2 (ja) * 2006-10-18 2016-02-09 アクセラ インコーポレーテッド 広い濃度範囲にわたる複数アナライトの光回折による測定
JP5320294B2 (ja) * 2006-10-26 2013-10-23 ベー.エル.アー.ハー.エム.エス ゲーエムベーハー プロバソプレシンまたはその断片および部分ペプチド、特にコペプチンまたはニューロフィジンiiを使用する、急性冠動脈症候群についてのリスク層化
WO2008128352A1 (en) * 2007-04-19 2008-10-30 Axela, Inc. Methods and compositions for signal amplification

Also Published As

Publication number Publication date
JP2015135338A (ja) 2015-07-27
WO2010049179A1 (en) 2010-05-06
CN103713137A (zh) 2014-04-09
CN106153943B (zh) 2019-02-15
CN102317788A (zh) 2012-01-11
ES2772930T3 (es) 2020-07-08
US9952229B2 (en) 2018-04-24
JP5785086B2 (ja) 2015-09-24
CN106153943A (zh) 2016-11-23
JP6055005B2 (ja) 2016-12-27
US20150293127A1 (en) 2015-10-15
US20110318766A1 (en) 2011-12-29
EP2356463A1 (en) 2011-08-17
JP2012507020A (ja) 2012-03-22
ES2645688T3 (es) 2017-12-07
EP2356463B1 (en) 2017-08-30
EP3199951B1 (en) 2019-11-20
US9116153B2 (en) 2015-08-25
EP3199951A1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
DK3199951T3 (da) Arginin-vasopressin-prohormon som prædiktiv biomarkør for diabetes
DK2466312T3 (da) Phosphoethanolamine som biomarkør for depression
IT1393131B1 (it) Controvento a ingobbamento limitato
DE602009000328D1 (de) Parallelmechanismus
DK3031825T3 (da) Immunbaserede aktivitetsassays for botulinum-toxin serotype a
HUE036885T2 (hu) Eljárás a bazofil-szint csökkentésére
BRPI0920069A2 (pt) biomarcadores
DK2350489T3 (da) Et mellemstykke til en stempel-side
BRPI0919682A2 (pt) mecanismo de fixação para um dispensador
BRPI0823115A2 (pt) Controle de acesso a serviço
DK2799627T3 (da) Et gribeorgan til lastbiler
DE112009001964A5 (de) Betätigungseinrichtung für Doppelkupplung
EP2265642A4 (en) BIOMARKERS
DK2278899T3 (da) Bryggemekanisme
EP2263086A4 (en) BIOMARKERS
DK2138386T3 (da) Holdeindretning til en rangeringsindretning
FI20080181A0 (fi) Laippakäämitys
DK2237972T3 (da) Løbestift til en rulle
DK2132185T3 (da) Pyrimidinyl-piperaziner nyttige som dopamin-D3/D2-receptorligander
DK2359142T3 (da) Importin 9 som biomarkør for skizofreni
EP2265641A4 (en) BIOMARKERS
DK2098653T3 (da) Rammekonstruktion til en væg
GB2468434B (en) A plectrum
DK2111774T3 (da) Bærestruktur til en gynge
FI20086031A0 (fi) Valkaisumenetelmä